Filing Flows › ClearPoint Neuro (CLPT) › Q3 2026 › vs Q2 2026
ClearPoint Neuro (CLPT) Q3 2026 vs Q2 2026 (quarter over quarter)
ClearPoint Neuro's revenue rose $1.2M (+11%) from $10.9M in Q2 2026 to $12.1M in Q3 2026.
ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%, net loss $7.5M, operating cash flow −$5.1M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $12.1M | $10.9M | $1.2M | +11% |
| Income tax benefit | $4K | $38K | −$34K | -89% |
| Net loss | $7.5M | $11.3M | −$3.9M | -34% |
| Costs & expenses | $19.5M | $22.3M | −$2.7M | -12% |
| Operating costs | $18.4M | $21.1M | −$2.7M | -13% |
| Interest & other, net | $1.1M | $1.1M | $1K | +0.1% |
| Cost of revenue | $5.0M | $4.2M | $846K | +20% |
| Research & development | $4.0M | $4.6M | −$614K | -13% |
| SG&A | $3.8M | $5.6M | −$1.7M | -31% |
| Other operating costs | $5.5M | $6.8M | −$1.2M | -18% |
| Operating cash sources | $7.5M | $11.3M | −$3.9M | -34% |
| Depreciation & amortization | $103K | $150K | −$47K | -31% |
| Share-based compensation | $1.9M | $2.3M | −$391K | -17% |
| Working capital & other | $365K | $1.9M | −$1.5M | -81% |
| Cash used in operations | $5.1M | $7.0M | −$1.9M | -27% |
| Net loss absorbed | $7.5M | $11.3M | −$3.9M | -34% |
Questions
How much did ClearPoint Neuro's revenue grow quarter over quarter in Q3 2026?
ClearPoint Neuro's revenue rose $1.2M (+11%) from $10.9M in Q2 2026 to $12.1M in Q3 2026.